Aytu BioPharma announces 1-for-20 reverse stock split

Aytu BioPharma announced a 1-for-20 reverse stock split of its outstanding common stock, effective on January 6. Beginning January 6, the company’s common stock will trade on a split-adjusted basis. The company’s board implemented the reverse stock split with the objective of regaining compliance with the $1.00 minimum bid price requirement of the Nasdaq Capital Market. The company has until May 22 to comply with this requirement.